Companies · Pharmaceuticals

iVeena Delivery Systems, Inc.

Salt Lake City · Pharmaceuticals

Diligence memoA one-page analyst read on iVeena Delivery Systems, Inc. — recommendation, valuation, rhythm, risks.
$5.6M
Total raised · real
3
Rounds
1.2×
Latest step-up
Top 57%
Sector rank · raised
Seed
Latest stage · inferred · Wed May 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

iVeena Delivery Systems, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 1.42× the median modeled value of Seed Pharmaceuticals companies in 2019–2021 (49 peers) — value vs value, same stage and era.
  • Within the normal band (142% of peer median) for its niche.
Dormant
  • Last raise 7.1 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

iVeena Delivery Systems, Inc. is one of 1613 Pharmaceuticals companies tracked from Salt Lake City. By capital raised it ranks mid-pack (ahead of 44% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(c)
Reg D exemption
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MPre-Seed · 2016-07-01 Raised $1.0M (real) Modeled valuation $47M (est)$1.0M$47MPre-Seed2016Seed · 2017-07-01 Raised $2.5M (real) Modeled valuation $95M (est)$2.5M$95MSeed2017Seed · 2019-05-29 Raised $2.1M (real) Modeled valuation $81M (est)$2.1M$81MSeed2019Seed · 2019-07-01 Raised $2.5M (real) Modeled valuation $94M (est)$2.5M$94MSeed2019+$2.5M+$2.1M+$2.5MCumulative $8.1M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$1.0M · 2016
Seed$2.5M · 2017
Seed extension$2.1M · 2019
Seed extension$2.5M · 2019

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$81.0M
Base estimate est.
$1.6M
Conservative case
$635.9M
Upside case
$10.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $47.3M · 2016-07-012016Seed · modeled $95.1M · 2017-07-01Seed · modeled $81.0M · 2019-05-29Seed · modeled $93.6M · 2019-07-012019
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
7.1 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$1.9M/yr
Capital velocity
10.0 yr
On record since
2016
First round
4
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.7× of median
This company$5.6M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.5× above median
This company$2.5M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.1× above median
This company$81.0M
Sector median$76.1M

Raised more than 44% of sector peers (real $). Modeled value above 51% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #13 of 49.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Wiesman Capital & Co., LLC · Seed Raised $4.0M · modeled $152.2M (est)Curzion Pharmaceuticals, Inc. · Seed Raised $3.5M · modeled $133.1M (est)Providence Therapeutics Inc. · Seed Raised $8.1M · modeled $132.2M (est)EnBiotix, Inc. · Seed Raised $6.6M · modeled $131.8M (est)Metuchen Pharmaceuticals, LLC · Seed Raised $3.1M · modeled $119.2M (est)VasoRx, Inc. · Seed Raised $4.7M · modeled $117.9M (est)Amplicore Inc. · Seed Raised $2.8M · modeled $107.1M (est)Lamassu Pharma, LLC · Seed Raised $2.7M · modeled $101.5M (est)Apertor Pharmaceuticals, Inc. · Seed Raised $3.0M · modeled $95.3M (est)Elgia Therapeutics, Inc. · Seed Raised $2.3M · modeled $88.6M (est)Pharmapotheca A, LLC · Seed Raised $3.1M · modeled $87.3M (est)ImmunoRx Pharma, Inc. · Seed Raised $2.7M · modeled $82.2M (est)iVeena Delivery Systems, Inc. (this company) Raised $5.6M · modeled $81.0M (est)iVeena Delivery Systems, Inc.
CompanyStageRaised · realValue · estvs peer med.
Wiesman Capital & Co., LLCSeed$4.0M$152.2M2.67×
Curzion Pharmaceuticals, Inc.Seed$3.5M$133.1M2.33×
Providence Therapeutics Inc.Seed$8.1M$132.2M2.32×
EnBiotix, Inc.Seed$6.6M$131.8M2.31×
Metuchen Pharmaceuticals, LLCSeed$3.1M$119.2M2.09×
VasoRx, Inc.Seed$4.7M$117.9M2.07×
Amplicore Inc.Seed$2.8M$107.1M1.88×
Lamassu Pharma, LLCSeed$2.7M$101.5M1.78×
Apertor Pharmaceuticals, Inc.Seed$3.0M$95.3M1.67×
Elgia Therapeutics, Inc.Seed$2.3M$88.6M1.55×
Pharmapotheca A, LLCSeed$3.1M$87.3M1.53×
ImmunoRx Pharma, Inc.Seed$2.7M$82.2M1.44×
iVeena Delivery Systems, Inc. this companySeed$5.6M$81.0M1.42×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$1.0M2016-07-01$5.6M$47.3M90%
Seed$2.5M2017-07-01$12.5M$95.1M90%
Seed$2.1M2019-05-29$10.7M$81.0M90%
Seed$2.5M2019-07-01$12.3M$93.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$1.0M2016-07-01
    • First recorded raise — entered as Pre-Seed.
  2. Seed$2.5M2017-07-01
    • Raised 12 mo later, in step with the ~13 mo sector norm.
    • Round 2.5× larger than the prior — scaling up.
  3. Seed$2.1M2019-05-29
    • Raised again after 23 mo — slower than the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • Switched to Rule 506(c) (was Rule 506(b)).
  4. Seed$2.5M2019-07-01
    • Came back fast: 1 mo vs the ~13 mo sector norm.
    • Round roughly the size of the prior one.
Intelligence
2020 ~Q2
Modeled next raise · ~12mo cadence
$2.8M
Modeled next size est.range $2.5M$4.5M
1.2×
Last step-up
$1.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
James Jensen6 other2016-07
David Robinson5 other2016-07
Barry Hanover2 other2016-07
Balamurali Ambati1 other2016-07
Jayakrishna Ambati1 other2016-07
Ned Weinshenker1 other2016-07
Balamurali U Ambati2017-07
Barry U Hanover2017-07
Gerald Simmons2016-07
Heffernan U Ron2019-05
James U Jensen2017-07
Jayakrishna U Ambati2017-07
Ned U Weinshenker2017-07
Robert U Dempsey2019-05
Registry & provenance

iVeena Delivery Systems, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1639219
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Inflammasome Therapeutics, Inc.PharmaSeed$6.2M$9.4Mnetwork2 shared operators · same stage
Beta Cat Pharmaceuticals, Inc.PharmaceuticalsSeed$5.5M$98.9Msame sector · same stage
Biostar Pharmaceuticals, Inc.PharmaceuticalsSeed$5.7M$80.6Msame sector · same stage
Sequel Pharmaceuticals IncPharmaceuticalsSeed$5.4M$38.0Msame sector · same stage
Crititech IncPharmaceuticalsSeed$6.0M$114.1Msame sector · same stage
Xtl Biopharmaceuticals LtdPharmaceuticalsSeed$5.3M$106.5Msame sector · same stage
Permeon Biologics, Inc.PharmaceuticalsSeed$6.0M$95.1Msame sector · same stage
iCeutica IncPharmaceuticalsSeed$6.0M$38.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
IVIEW Therapeutics, Inc.PharmaceuticalsSeries B$67.7M85%
Complexa Inc.PharmaceuticalsSeries C$386.0M82%
IMC CorpPharmaceuticalsSeries A$154.9M81%
Innocrin Pharmaceuticals Holdings, LLCPharmaceuticalsSeries B$204.0M79%
Immunovant, Inc.PharmaceuticalsGrowth/Late$5.0B79%
Pharmaceutics International, Inc.PharmaceuticalsSeries D+$124.0M79%
Insigna, Inc.PharmaceuticalsSeries A$16.0M79%
Citius Pharmaceuticals, Inc.PharmaceuticalsSeries B$542.1M78%
Frequently asked
How much funding has iVeena Delivery Systems, Inc. raised?
iVeena Delivery Systems, Inc. has raised approximately $5.6M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is iVeena Delivery Systems, Inc.'s estimated valuation?
Provath's modeled valuation for iVeena Delivery Systems, Inc. is approximately $81.0M (modeled range $1.6M–$635.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is iVeena Delivery Systems, Inc. at?
iVeena Delivery Systems, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Wed May 29.
What does iVeena Delivery Systems, Inc. do and where is it based?
iVeena Delivery Systems, Inc. operates in the Pharmaceuticals sector, based in Salt Lake City.
Explore related

See where iVeena Delivery Systems, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at iVeena Delivery Systems, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.